nuclear medicine

(redirected from Radionuclide imaging)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to Radionuclide imaging: Radionuclide scanning

nuclear medicine

[′nü·klē·ər ′med·ə·sən]
(medicine)
A branch of medicine in which radioactive pharmaceuticals are used for imaging or other diagnostic studies.
References in periodicals archive ?
Hendel, MD, FACC, FAHA, FASNC, and Chair of the Cardiac Radionuclide Imaging Writing Group that developed the 2009 AUC for RNI.
Based on the results of this extensive clinical testing, Gensia believes that the efficacy of the GenESA System is equivalent to exercise when used in conjunction with ECG, echocardiography and radionuclide imaging in the diagnosis of coronary artery disease.
CARDIOsphere was comparable to radionuclide imaging in identifying the anatomic location of disease.
The GenESA System combines a novel drug, arbutamine, and a computer- controlled, closed-loop drug delivery system designed to pharmacologically stress the heart to aid in the diagnosis of coronary artery disease (CAD) when used in conjunction with ECG, echocardiography and radionuclide imaging.
Many of these patients may then be tested using echocardiography, a widely used ultrasound imaging modality for evaluating heart structure and function, or radionuclide imaging, which involves the injection of radioisotopes and the use of a gamma camera to detect perfusion defects indicating the presence of CAD.
5 million radionuclide imaging perfusion scans performed each year in the United States for the diagnosis of CAD.
The GenESA System is designed for use in the diagnosis of coronary artery disease in conjunction with electrocardiography, echocardiography and radionuclide imaging.
The GenESA System is designed for use in the diagnosis of coronary artery disease in conjunction with the three major modalities for testing for coronary artery disease: electrocardiography (ECG), echocardiography and radionuclide imaging.
Bio-Imaging Technologies of West Trenton, applies advanced technologies such as magnetic resonance imaging, radionuclide imaging and computer-assisted image analysis to visualize and measure drug and medical device effects during the clinical development and pre-clinical testing process.
NASDAQ: GNSA) today announced that, based on the company's analysis of safety and efficacy results with the GenESA System in international multicenter Phase 3 clinical trials, it plans to file regulatory submissions in the United States, Western Europe and Canada for the GenESA System for use in the diagnosis of coronary artery disease, in conjunction with electrocardiography (ECG), echocardiography (echo) and radionuclide imaging.
Bio-Imaging Technologies of West Trenton applies advanced technologies such as magnetic resonance imaging, radionuclide imaging and computer-assisted image analysis to visualize and measure drug and medical device effects during the clinical development and pre-clinical testing process.

Full browser ?